CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), recently received market approval from the U.S. Food and Drug Administration for XYNTHATM (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis. The peptide ligand, used in the purification process during the manufacture of XYNTHA, was discovered utilizing Dyax’s proprietary phage display library and is part of the Company’s Licensing and Funded Research Program (LFRP). XYNTHA is now distinguished as the only recombinant factor VIII treatment to utilize an entirely synthetic purification process.
